IQVIA (IQV) closed at $266.79 on Oct 16, 2026, down 1.6% on the day. The stock is down 1.0% over the past month, up 30.8% over three months, up 18.4% year to date and up 31.3% over the past year. It trades 3.8% below its 52-week high of $277.40 and 72.7% above its 52-week low of $154.50. The close sits above its 50-day moving average ($260.02) and above its 200-day moving average ($207.74).
IQV is scheduled to report earnings on Oct 27, 2026, before market open.
IQV options were pricing 44% at-the-money implied volatility on Oct 13, 2026, an IV rank of 56 over the past year. Form 4 filings over the last 90 days show no open-market purchases and 9 open-market sales by insiders.
IQVIA is scheduled to report on Oct 27, 2026, before market open.
Yes — the Oct 16, 2026 close of $266.79 is 28.4% above the 200-day average of $207.74.
IQV closed 3.8% below its 52-week high of $277.40.
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
